Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”
Abstract
:Simple Summary
Abstract
1. Introduction
2. Locoregional Treatment
3. Metastases Treatment
- Patients with brain metastases without extracranial disease:
- Patients with isolated liver involvement:
- Patients with lung metastases:
- Patients with bone metastases:
4. Tools for Early Diagnosis of Oligometastatic Disease
5. Conclusions and Future Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Pérez-García, J.; Cortez, P.; Gion, M.; Cortés, J. Can we cure oligometastatic disease? A practical point of view. Curr. Opin. Oncol. 2020, 32, 568–574. [Google Scholar] [CrossRef] [PubMed]
- Pagani, O.; Senkus, E.; Wood, W.; Colleoni, M.; Cufer, T.; Kyriakides, S.; Costa, A.; Winer, E.P.; Cardoso, F. International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured? J. Natl. Cancer Inst. 2010, 102, 456–463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Danna, E.A.; Sinha, P.; Gilbert, M.; Clements, V.K.; Pulaski, B.A.; Ostrand-Rosenberg, S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004, 64, 2205–2211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sandri, M.T.; Zorzino, L.; Cassatella, M.C.; Bassi, F.; Luini, A.; Casadio, C.; Botteri, E.; Rotmensz, N.; Adamoli, L.; Nolè, F. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann. Surg. Oncol. 2010, 17, 1539–1545. [Google Scholar] [CrossRef] [PubMed]
- Salo, M. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol. Scand. 1992, 36, 201–220. [Google Scholar] [CrossRef]
- Khan, S.A. Primary tumor resection in stage IV breast cancer: Consistent benefit, or consistent bias? Ann. Surg. Oncol. 2007, 14, 3285–3287. [Google Scholar] [CrossRef] [Green Version]
- Harris, E.; Barry, M.; Kell, M.R. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann. Surg. Oncol. 2013, 20, 2828–2834. [Google Scholar] [CrossRef]
- Di Lascio, S.; Pagani, O. Oligometastatic breast cancer: A shift from palliative to potentially curative treatment? Breast Care 2014, 9, 7–14. [Google Scholar] [CrossRef] [Green Version]
- Swain, S.M.; Kim, S.-B.; Cortés, J.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.-M.; Schneeweiss, A.; Knott, A.; et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. Oncol. 2013, 14, 461–471. [Google Scholar] [CrossRef] [Green Version]
- Rosier, L.; Wang, Y.; Lee, J.-H.; Daily, K. Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade? Breast Cancer Res. Treat. 2022, 191, 375–383. [Google Scholar] [CrossRef]
- Soran, A.; Ozmen, V.; Ozbas, S.; Karanlik, H.; Muslumanoglu, M.; Igci, A.; Canturk, Z.; Utkan, Z.; Ozaslan, C.; Evrensel, T.; et al. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann. Surg. Oncol. 2018, 25, 3141–3149. [Google Scholar] [CrossRef] [PubMed]
- Soran, A.; Ozmen, V.; Ozbas, S.; Karanlik, H.; Muslumanoglu, M.; Igci, A.; Canturk, N.Z.; Utkan, Z.; Evrensel, T.; Sezgin, E. Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial. J. Am. Coll. Surg. 2021, 233, 742–751.e5. [Google Scholar] [CrossRef]
- Badwe, R.; Hawaldar, R.; Nair, N.; Kaushik, R.; Parmar, V.; Siddique, S.; Budrukkar, A.; Mittra, I.; Gupta, S. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. Lancet. Oncol. 2015, 16, 1380–1388. [Google Scholar] [CrossRef]
- Fitzal, F.; Bjelic-Radisic, V.; Knauer, M.; Steger, G.; Hubalek, M.; Balic, M.; Singer, C.; Bartsch, R.; Schrenk, P.; Soelkner, L.; et al. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann. Surg. 2019, 269, 1163–1169. [Google Scholar] [CrossRef]
- Khan, S.A.; Zhao, F.; Goldstein, L.J.; Cella, D.; Basik, M.; Golshan, M.; Julian, T.B.; Pockaj, B.A.; Lee, C.A.; Razaq, W.; et al. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2022, 40, 978–987. [Google Scholar] [CrossRef] [PubMed]
- Soran, A.; Dogan, L.; Isik, A.; Ozbas, S.; Trabulus, D.C.; Demirci, U.; Karanlik, H.; Soyder, A.; Dag, A.; Bilici, A.; et al. The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study. Ann. Surg. Oncol. 2021, 28, 5048–5057. [Google Scholar] [CrossRef]
- Koleva-Kolarova, R.G.; Oktora, M.P.; Robijn, A.L.; Greuter, M.J.W.; Reyners, A.K.L.; Buskens, E.; de Bock, G.H. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat. Rev. 2017, 55, 16–25. [Google Scholar] [CrossRef] [Green Version]
- Gobbini, E.; Ezzalfani, M.; Dieras, V.; Bachelot, T.; Brain, E.; Debled, M.; Jacot, W.; Mouret-Reynier, M.A.; Goncalves, A.; Dalenc, F.; et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur. J. Cancer 2018, 96, 17–24. [Google Scholar] [CrossRef]
- Dorn, P.L.; Meriwether, A.; LeMieux, M.; Weichselbaum, R.R.; Chmura, S.J.; Hasan, Y. Patterns of Distant Failure and Progression in Breast Cancer: Implications for the Treatment of Oligometastatic Disease. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, S643. [Google Scholar] [CrossRef]
- Gamucci, T.; Pizzuti, L.; Natoli, C.; Mentuccia, L.; Sperduti, I.; Barba, M.; Sergi, D.; Iezzi, L.; Maugeri-Saccà, M.; Vaccaro, A.; et al. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Cancer Biol. Ther. 2019, 20, 192–200. [Google Scholar] [CrossRef]
- Chmura, S.J.; Winter, K.A.; Woodward, W.A.; Borges, V.F.; Salama, J.K.; Al-Hallaq, H.A.; Matuszak, M.; Milano, M.T.; Jaskowiak, N.T.; Bandos, H.; et al. NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J. Clin. Oncol. 2022, 40, 1007. [Google Scholar] [CrossRef]
- Soffietti, R.; Abacioglu, U.; Baumert, B.; Combs, S.E.; Kinhult, S.; Kros, J.M.; Marosi, C.; Metellus, P.; Radbruch, A.; Villa Freixa, S.S.; et al. Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European Association of Neuro-Oncology (EANO). Neuro. Oncol. 2017, 19, 162–174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Patchell, R.A.; Tibbs, P.A.; Walsh, J.W.; Dempsey, R.J.; Maruyama, Y.; Kryscio, R.J.; Markesbery, W.R.; Macdonald, J.S.; Young, B. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990, 322, 494–500. [Google Scholar] [CrossRef] [PubMed]
- Le Rhun, É.; Dhermain, F.; Noël, G.; Reyns, N.; Carpentier, A.; Mandonnet, E.; Taillibert, S.; Metellus, P. Recommandations de l’Anocef pour la prise en charge des métastases cérébrales. Cancer/Radiothérapie 2015, 19, 66–71. [Google Scholar] [CrossRef] [PubMed]
- Bailleux, C.; Eberst, L.; Bachelot, T. Treatment strategies for breast cancer brain metastases. Br. J. Cancer 2021, 124, 142–155. [Google Scholar] [CrossRef] [PubMed]
- Patchell, R.A.; Tibbs, P.A.; Regine, W.F.; Dempsey, R.J.; Mohiuddin, M.; Kryscio, R.J.; Markesbery, W.R.; Foon, K.A.; Young, B. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998, 280, 1485–1489. [Google Scholar] [CrossRef]
- Ruiz, A.; Sebagh, M.; Wicherts, D.A.; Castro-Benitez, C.; van Hillegersberg, R.; Paule, B.; Castaing, D.; Vibert, E.; Cunha, A.S.; Cherqui, D.; et al. Long-term survival and cure model following liver resection for breast cancer metastases. Breast Cancer Res. Treat. 2018, 170, 89–100. [Google Scholar] [CrossRef] [Green Version]
- Tasleem, S.; Bolger, J.C.; Kelly, M.E.; Boland, M.R.; Bowden, D.; Sweeney, K.J.; Malone, C. The role of liver resection in patients with metastatic breast cancer: A systematic review examining the survival impact. Ir. J. Med. Sci. 2018, 187, 1009–1020. [Google Scholar] [CrossRef]
- Golse, N.; Adam, R. Liver Metastases from Breast Cancer: What Role for Surgery? Indications and Results. Clin. Breast Cancer 2017, 17, 256–265. [Google Scholar] [CrossRef]
- Adam, R.; Aloia, T.; Krissat, J.; Bralet, M.-P.; Paule, B.; Giacchetti, S.; Delvart, V.; Azoulay, D.; Bismuth, H.; Castaing, D. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann. Surg. 2006, 244, 897–898. [Google Scholar] [CrossRef]
- Caralt, M.; Bilbao, I.; Cortés, J.; Escartín, A.; Lázaro, J.L.; Dopazo, C.; Olsina, J.J.; Balsells, J.; Charco, R. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann. Surg. Oncol. 2008, 15, 2804–2810. [Google Scholar] [CrossRef] [PubMed]
- Dittmar, Y.; Altendorf-Hofmann, A.; Schüle, S.; Ardelt, M.; Dirsch, O.; Runnebaum, I.B.; Settmacher, U. Liver resection in selected patients with metastatic breast cancer: A single-centre analysis and review of literature. J. Cancer Res. Clin. Oncol. 2013, 139, 1317–1325. [Google Scholar] [CrossRef] [PubMed]
- Hoffmann, K.; Franz, C.; Hinz, U.; Schirmacher, P.; Herfarth, C.; Eichbaum, M.; Büchler, M.W.; Schemmer, P. Liver resection for multimodal treatment of breast cancer metastases: Identification of prognostic factors. Ann. Surg. Oncol. 2010, 17, 1546–1554. [Google Scholar] [CrossRef] [PubMed]
- Chua, T.C.; Saxena, A.; Liauw, W.; Chu, F.; Morris, D.L. Hepatic resection for metastatic breast cancer: A systematic review. Eur. J. Cancer 2011, 47, 2282–2290. [Google Scholar] [CrossRef] [PubMed]
- Ruiz, A.; van Hillegersberg, R.; Siesling, S.; Castro-Benitez, C.; Sebagh, M.; Wicherts, D.A.; de Ligt, K.M.; Goense, L.; Giacchetti, S.; Castaing, D.; et al. Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison. Eur. J. Cancer 2018, 95, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Ruiz, A.; Castro-Benitez, C.; Sebagh, M.; Giacchetti, S.; Castro-Santa, E.; Wicherts, D.A.; van Hillegersberg, R.; Paule, B.; Castaing, D.; Morère, J.-F.; et al. Repeat Hepatectomy for Breast Cancer Liver Metastases. Ann. Surg. Oncol. 2015, 22 (Suppl. S3), S1057–S1066. [Google Scholar] [CrossRef] [PubMed]
- Taşçi, Y.; Aksoy, E.; Taşkın, H.E.; Aliyev, S.; Moore, H.; Ağcaoğlu, O.; Birsen, O.; Siperstein, A.; Berber, E. A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver. HPB Off. J. Int. Hepato Pancreato Biliary Assoc. 2013, 15, 789–793. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Friedel, G.; Pastorino, U.; Ginsberg, R.J.; Goldstraw, P.; Johnston, M.; Pass, H.; Putnam, J.B.; Toomes, H. Results of lung metastasectomy from breast cancer: Prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 2002, 22, 335–344. [Google Scholar] [CrossRef] [Green Version]
- Fan, J.; Chen, D.; Du, H.; Shen, C.; Che, G. Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: A systematic review and meta-analysis. J. Thorac. Dis. 2015, 7, 1441–1451. [Google Scholar] [CrossRef]
- Palma, D.A.; Olson, R.; Harrow, S.; Gaede, S.; Louie, A.V.; Haasbeek, C.; Mulroy, L.; Lock, M.; Rodrigues, G.B.; Yaremko, B.P.; et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020, 38, 2830–2838. [Google Scholar] [CrossRef]
- Viani, G.A.; Gouveia, A.G.; Louie, A.V.; Korzeniowski, M.; Pavoni, J.F.; Hamamura, A.C.; Moraes, F.Y. Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2021, 164, 245–250. [Google Scholar] [CrossRef] [PubMed]
- Dürr, H.R.; Müller, P.E.; Lenz, T.; Baur, A.; Jansson, V.; Refior, H.J. Surgical treatment of bone metastases in patients with breast cancer. Clin. Orthop. Relat. Res. 2002, 396, 191–196. [Google Scholar]
- Milano, M.T.; Katz, A.W.; Zhang, H.; Huggins, C.F.; Aujla, K.S.; Okunieff, P. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2019, 131, 45–51. [Google Scholar] [CrossRef]
- Lequaglie, C.; Massone, P.B.; Giudice, G.; Conti, B. Gold standard for sternectomies and plastic reconstructions after resections for primary or secondary sternal neoplasms. Ann. Surg. Oncol. 2002, 9, 472–479. [Google Scholar] [CrossRef] [PubMed]
- Noble, J.; Sirohi, B.; Ashley, S.; Ladas, G.; Smith, I. Sternal/para-sternal resection for parasternal local recurrence in breast cancer. Breast 2010, 19, 350–354. [Google Scholar] [CrossRef] [PubMed]
- Trovo, M.; Furlan, C.; Polesel, J.; Fiorica, F.; Arcangeli, S.; Giaj-Levra, N.; Alongi, F.; Del Conte, A.; Militello, L.; Muraro, E.; et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2018, 126, 177–180. [Google Scholar] [CrossRef]
- Pérez-García, J.M.; Gebhart, G.; Ruiz Borrego, M.; Stradella, A.; Bermejo, B.; Schmid, P.; Marmé, F.; Escrivá-de-Romani, S.; Calvo, L.; Ribelles, N.; et al. Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): A multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet. Oncol. 2021, 22, 858–871. [Google Scholar] [CrossRef]
- Garcia-Murillas, I.; Schiavon, G.; Weigelt, B.; Ng, C.; Hrebien, S.; Cutts, R.J.; Cheang, M.; Osin, P.; Nerurkar, A.; Kozarewa, I.; et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 2015, 7, 302ra133. [Google Scholar] [CrossRef]
- Routman, D.M.; Chera, B.S.; Gupta, G.P. Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis. Cancer J. 2020, 26, 116–123. [Google Scholar] [CrossRef]
- Soh, J.; Komoike, Y.; Mitsudomi, T. Surgical therapy for pulmonary metastasis of breast cancer. Transl. Cancer Res. 2020, 9, 5044–5052. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gion, M.; Saavedra, C.; Perez-Garcia, J.; Cortes, J. Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”. Cancers 2022, 14, 5229. https://doi.org/10.3390/cancers14215229
Gion M, Saavedra C, Perez-Garcia J, Cortes J. Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”. Cancers. 2022; 14(21):5229. https://doi.org/10.3390/cancers14215229
Chicago/Turabian StyleGion, Maria, Cristina Saavedra, Jose Perez-Garcia, and Javier Cortes. 2022. "Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”" Cancers 14, no. 21: 5229. https://doi.org/10.3390/cancers14215229